Cwm LLC Sells 1,767 Shares of Haemonetics Co. (NYSE:HAE)

Cwm LLC decreased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,868 shares of the medical instruments supplier’s stock after selling 1,767 shares during the period. Cwm LLC owned approximately 0.07% of Haemonetics worth $2,896,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Knights of Columbus Asset Advisors LLC boosted its stake in Haemonetics by 345.4% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 44,561 shares of the medical instruments supplier’s stock valued at $3,810,000 after buying an additional 34,556 shares during the period. Keene & Associates Inc. boosted its stake in Haemonetics by 3.1% during the fourth quarter. Keene & Associates Inc. now owns 8,780 shares of the medical instruments supplier’s stock valued at $751,000 after buying an additional 268 shares during the period. Louisiana State Employees Retirement System bought a new stake in Haemonetics during the fourth quarter valued at $1,223,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Haemonetics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock valued at $1,956,000 after buying an additional 838 shares during the period. Finally, ABLE Financial Group LLC boosted its stake in Haemonetics by 28.4% during the fourth quarter. ABLE Financial Group LLC now owns 7,251 shares of the medical instruments supplier’s stock valued at $620,000 after buying an additional 1,606 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on HAE shares. Barrington Research reissued an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

Haemonetics Trading Up 1.4 %

Shares of HAE stock opened at $86.23 on Thursday. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The business has a 50-day moving average price of $79.71 and a two-hundred day moving average price of $82.64. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $95.26. The firm has a market cap of $4.38 billion, a P/E ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. The firm had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.85 earnings per share. Equities analysts anticipate that Haemonetics Co. will post 3.95 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.